Last updated: 23 July 2019 at 7:58am EST

Walter Blattler Net Worth




The estimated Net Worth of Walter Blattler is at least $4.99 million dollars as of 13 April 2007. Walter Blattler owns over 23,500 units of Immunogen stock worth over $3,901,876 and over the last 21 years Walter sold IMGN stock worth over $1,088,469.

Walter Blattler IMGN stock SEC Form 4 insiders trading

Walter has made over 10 trades of the Immunogen stock since 2004, according to the Form 4 filled with the SEC. Most recently Walter sold 23,500 units of IMGN stock worth $140,060 on 13 April 2007.

The largest trade Walter's ever made was exercising 272,500 units of Immunogen stock on 23 March 2007 worth over $643,100. On average, Walter trades about 65,484 units every 74 days since 2003. As of 13 April 2007 Walter still owns at least 124,900 units of Immunogen stock.

You can see the complete history of Walter Blattler stock trades at the bottom of the page.



What's Walter Blattler's mailing address?

Walter's mailing address filed with the SEC is , , , , .

Insiders trading at Immunogen

Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... et Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.



What does Immunogen do?

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.



Complete history of Walter Blattler stock trades at Immunogen

Initié
Trans.
Transaction
Prix ​​total
Walter Blattler
Vice-président exécutif
Vente $140,060
13 Apr 2007
Walter Blattler
Vice-président exécutif
Vente $948,409
13 Apr 2007
Walter Blattler
Vice-président exécutif
Exercice d'option $455,437
27 Mar 2007
Walter Blattler
Vice-président exécutif
Exercice d'option $208,295
26 Mar 2007
Walter Blattler
Vice-président exécutif
Exercice d'option $643,100
23 Mar 2007
Walter Blattler
Vice-président exécutif
Exercice d'option $24,180
22 Mar 2007
Walter Blattler
Vice-président exécutif
Exercice d'option $187,500
6 Mar 2006
Walter Blattler
Vice-président exécutif
Exercice d'option $97,000
9 Mar 2005
Walter Blattler
Vice-président exécutif
Exercice d'option $231,832
7 Jun 2004
Walter Blattler
Vice-président exécutif
Exercice d'option $51,300
7 Jun 2004


Immunogen executives and stock owners

Immunogen executives and other stock owners filed with the SEC include: